Mavacamten treatment over 24 weeks in patients with symptomatic oHCM significantly reduced resting and Valsalva LVOT gradients (both p<0.001) and improved NYHA class in 70% of patients.
Observational (n=23)
No
Does mavacamten improve LVOT gradients and symptoms in patients with symptomatic obstructive hypertrophic cardiomyopathy?
In a real-world Australian cohort, mavacamten significantly reduced LVOT gradients and improved NYHA class in patients with symptomatic obstructive hypertrophic cardiomyopathy over 24 weeks.
p-value: p=<0.001
BACKGROUND Valsalva, 37±36 mmHg; both p<0.001). Although statistically significant, the LVEF drop does not appear clinically significant (66% to 62%; p=0.02). LV global longitudinal function remained largely static across 24 weeks (-15.3% to -15.6%; p=0.6). A total of 70% of patients experienced at least one NYHA class improvement. Patient adherence was high, with 99% of all scheduled appointments attended. A total of 39 treatment-emergent adverse events occurred, of which 38% were cardiac-related. Over 24 weeks, three of 23 (13%) patients permanently discontinued mavacamten. CONCLUSIONS Our results provide novel real-world Australian data on the use of mavacamten in patients with oHCM. Approximately 70% of patients experienced significant clinical and echocardiographic improvement in first 6 months after drug initiation, with a tolerable safety profile.
So et al. (Thu,) conducted a observational in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) (n=23). Mavacamten was evaluated on at rest and Valsalva LVOT gradients, LVEF, LV global longitudinal function, and NYHA class (p=<0.001). Mavacamten treatment over 24 weeks in patients with symptomatic oHCM significantly reduced resting and Valsalva LVOT gradients (both p<0.001) and improved NYHA class in 70% of patients.